We sought to define cellular immune mechanisms of synergy between tumor-antigen-targeted monoclonal antibodies and chemotherapy. Established B16 melanoma in mice was treated with cytotoxic doses of cyclophosphamide in combination with an antibody targeting tyrosinase-related protein 1 (aTRP1), a native melanoma differentiation antigen. We find that Fcg receptors are required for efficacy, showing that antitumor activity of combination therapy is immune mediated. Rag1 À/À mice deficient in adaptive immunity are able to clear tumors, and thus innate immunity is sufficient for efficacy. Furthermore, previously treated wild-type mice are not significantly protected against tumor reinduction, as compared with mice inoculated with irradiated B16 alone, consistent with a primarily innate immune mechanism of action of chemoimmunotherapy. In contrast, mice deficient in both classical natural killer (NK) lymphocytes and nonclassical innate lymphocytes (ILC) due to deletion of the IL2 receptor common gamma chain IL2gc À/À ) are refractory to chemo-immunotherapy. Classical NK lymphocytes are not critical for treatment, as depletion of NK1.1 þ cells does not impair antitumor effect.
Introduction
Immunotherapy has yielded exciting results in clinical cancer care. Ipilimumab (Yervoy; Bristol-Myers Squibb), an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, was FDA approved in 2011 for the treatment of metastatic melanoma; pembrolizumab, an anti-programmed cell death 1 (PD-1) antibody (pembrolizumab, Keytruda; Merck), was approved for melanoma in 2014 with a reported response rate of 38% (1, 2) . The response rate to ipilimumab doubles when it is combined with dacarbazine, and multiple studies combining pembrolizumab with chemotherapy are ongoing (3) (4) (5) . However, the role of chemotherapy in combination with immunotherapy is yet to be established. It is not known how chemotherapy may affect overall survival in patients treated with chemo-immunotherapy, particularly as the reported survival at 4 years after treatment with the combination did not appear to differ significantly from survival rates with ipilimumab alone (6) .
Similarly, chemotherapy is known to enhance the response rates of tumor-antigen-targeted monoclonal antibodies (mAb), and the combination regimens have documented efficacy against solid tumors of the breast, head and neck, and colon. Tumorantigen-targeted mAbs used as a single agent have limited clinical response rates of 8% to 10%, and when used in combination with radiotherapy or chemotherapy, the response rates increase up to 50% (7) . Thus, chemotherapy significantly improves the clinical benefit of tumor-antigen-targeted mAbs. The antitumor activity of combination therapy using tumor-antigen-targeted mAb is complex, and effector mechanisms via both innate and adaptive immunity have been proposed. Furthermore, results from recent studies have suggested that there are commonalities in therapyinduced immunologic mechanisms of response between solid tumor types (8) . An understanding of the mechanisms whereby chemotherapy improves the efficacy of tumor-antigen-targeted mAbs would inform the design of future combination trials using tumor-antigen-targeted mAbs as well as other immunotherapies.
Tumor-antigen-targeted mAbs can eliminate cancer cells in patients through both immune-mediated and non-immunemediated mechanisms (9) . Some antibodies, such as trastuzumab (Herceptin; Genentech), target an oncogenic protein HER2/neu, and are hypothesized to disrupt oncogenic signaling pathways (10) . Other antibody targets, such as CD20 (Rituxan; Genentech), have no established role in carcinogenesis, but ligation of these molecules is nevertheless efficacious in the treatment of lymphoma, most likely via binding of effector cells to the Fc domain of the tumor-bound antibody (11) . Established immune mechanisms for antitumor mAbs include complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and induction of adaptive immunity. CDC occurs when complement binds and lyses tumor cells ligated by antibody. In contrast, ADCC occurs when activating Fc receptors, expressed on the surface of innate immune cells, bind to the Fc domain of antibodies and activate killing mechanisms. Fc receptor genotype has been shown to affect clinical response to many antitumor antibodies, validating the importance of this mechanism in patients (12, 13) . Finally, adaptive immunity has been proposed as a contributor to antitumor efficacy, and preclinical studies have shown that tumors coated with antibody can be phagocytosed by antigen-presenting cells, improving the generation of T-cell responses against the tumor and yielding a vaccine effect (14) .
To define the mechanisms of synergy between chemotherapy and mAbs, we treated established melanoma with a combination of an IgG2a murine antibody to tyrosinase-related protein 1 (aTRP1) and cyclophosphamide. TRP1 is a native self-differentiation antigen against which normal tolerance is well established, and it is expressed by melanomas and melanocytes. A humanized analogue to TRP1 has been tested in clinical trials (15) . Previous studies have shown that aTRP1 protects mice from B16 melanoma when administered synchronously but aTRP1 is not protective when administered after tumor engraftment (16) . It is important to note that although TRP1 is an intracellular melanosome antigen, it is expressed on the tumor-cell surface in vivo (17, 18) , and efficacy of aTRP1 monotherapy for nonestablished tumors is dependent on Fc receptors (19) . However, the specific cellular effector mechanism is unknown with roles proposed in the literature for natural killer (NK) cells, macrophages, and CD4 þ T cells (19) (20) (21) .
When established melanoma is treated with aTRP1 and cyclophosphamide, we find that the innate immune system is fully competent to mediate tumor clearance in the absence of adaptive immunity, but that Fc receptors are required. Furthermore, we see no significant evidence that antibody therapy produces long-term protection against reinoculation with B16. We find a requirement for innate lymphocytes (ILC), as treatment is not effective in animals with a deficiency in the gamma chain of the IL2 receptor (IL2gc (19, 25, 26) . ILCs lack rearranged antigen receptors and function in lymphoid organogenesis, tissue remodeling, antimicrobial immunity, and inflammation (27) . This work suggests a potential role for innate lymphoid cells in the efficacy of chemo-immunotherapy using tumor-antigen-targeted mAbs. 
Materials and Methods

Mice
Production of antibodies
Hybridoma cell lines were grown in SFM hybridoma medium (Life Technologies), and then transferred into the small chamber of CELLine bioreactor flask (Integra Biosciences AG). After 2 weeks, the supernatant was removed and filtered with a 0.22-mm filter (Fisher Scientific) and antibody was purified using PD-10 desalting columns according to the manufacturer's protocol (GE Healthcare). Each dose of TA99 was titrated for antitumor activity in mice synchronously injected with B16 tumor cells before use in experiments.
Tumor inoculation and monitoring of tumor growth
Mice were inoculated s.c. on the right flank with 75,000 B16 cells. Tumor growth was monitored via biweekly measurement of perpendicular diameters and height using a caliper. Animals that were moribund or had tumors greater than 300 mm 3 were scored as dead in accordance with our IACUC protocol.
Cyclophosphamide and mAb treatment
Mice were injected i.p. with cyclophosphamide (Baxter) at 225 to 250 mg/kg on day 4 to 7 after tumor inoculation. One day after cyclophosphamide was administered, mice were injected i.p. with 500 mg of aTRP1 followed by two injections per week of the same dose for a total of seven doses.
In vivo antibody depletions
Mice were injected i.p. on day À1 with 500 mg aNK1.1 (PK136; ATCC), or with 250 mg aCD90 (30H12; Bio X cell), or with 500 mg aCD8; injections were repeated weekly for the duration of the experiment.
Flow cytometry
For analysis of tumor-infiltrating leukocytes, mice bearing tumors at least 300 mm 3 (newly scored dead on survival curve) were sacrificed by CO 2 inhalation and tumors were dissected. The tumor mass was homogenized, digested with 0.4 mg/mL collagenase (Sigma-Aldrich), incubated at 37 C for 1 hour, and strained through 100-mm nylon filters (Fisher Scientific). Cells were incubated with antibodies for 25 
Statistical analysis
Statistical analysis was performed using Prism Software (GraphPad Software, Inc.). Survival analysis was performed using the log-rank (Mantel-Cox) test with Bonferroni correction. Significance was defined at a P value of <0.05, using a nonparametric Mann-Whitney t test. Bonferroni correction was used for multigroup comparisons.
Results
Synergistic antitumor benefit is achieved through treatment of established melanoma with cytotoxic dose of cyclophosphamide combined with anti-TRP1 mAb
To understand the mechanism of combination therapy, including antitumor antibody and chemotherapy, we established a murine treatment model using B16 melanoma ( aTRP1 combined with cyclophosphamide (CY) has efficacy in established melanoma. A, C57BL/6 mice (n ¼ 9-11/group) were inoculated with B16 on day 0 and treated with 250 mg/kg of cyclophosphamide on day 7 followed by 0.5 mg of aTRP1 or isotype control (C44) biweekly for 3 weeks. Tumor volumes were assessed biweekly. B, mean tumor size is shown for each group. Note that curves are cut off when mice started to die in each group and can distort the growth curves. C, survival was statistically increased in the combination therapy group compared with that of cyclophosphamide alone (P ¼ 0.0002), aTRP1 alone (P ¼ 0.0002), and untreated (P < 0.0001). C and D, the same protocol was applied to mice on the B6.129 background with or without deletion of the Fc receptor common g chain (FcgR clinically in patients with cancer, this growth arrest was temporary, and all animals receiving only cyclophosphamide subsequently grew large tumors ( Fig. 1B and 1C) . Meanwhile, aTRP1 mAb alone had minimal impact on the growth of established tumors. The addition of aTRP1 to cyclophosphamide treatment significantly improved survival, with some animals displaying longterm responses (Fig. 1B and C) . Pigmented scars were observed at the site of tumor inoculation in long-term responders, showing appropriate tumor engraftment. Cyclophosphamide has also been reported to have favorable immunologic effects at lower doses through the selective depletion of regulatory T cells (28) . Although low-dose cyclophosphamide (150 mg/kg) synergized with aTRP1, it did not produce long-term responders, the clinically desired outcome, even when treatment was administered before tumors were visible (day 4; Supplementary Fig. S1 ). Thus, a treatment model using cytotoxic doses of cyclophosphamide was used for all subsequent studies as it achieves the clinically relevant outcome of long-term survival benefit in established tumors.
Efficacy of combined therapy with aTRP1 and cyclophosphamide is Fc receptor-dependent
Tumor-antigen-targeted antibodies induce tumor regression through both immune and nonimmune mechanisms. Antibodies can mediate tumor-cell elimination in a mechanism dependent on Fc receptors expressed on the surface of immune cells (29) . Thus, we investigated whether the mechanism of action of combination therapy was dependent on ligation of Fc receptors by the antibody. Prior work with aTRP1 has shown that it prevents tumor engraftment as a single agent in prophylactic models (administered synchronously with tumor) in a manner dependent on activating Fc receptors (19) . This is consistent with the proposed mechanisms of action of multiple antibodies in clinical use, including aher2neu and aCD20, antibodies known to act via Fc receptors (30) . We tested our combination regimen in mice deficient in the common g chain required for expression of activating Fc receptors ( Fig. 1D and E; ref. 31 ). Treatment was not effective in Fc receptor-deficient animals, confirming that chemotherapy does not alter the requirement for Fc receptors and that the immune system plays a necessary role in the efficacy of our combination treatment.
The innate immune system is competent to induce tumor clearance during therapy with aTRP1 þ cyclophosphamide By binding to Fc receptors, antibodies can eliminate tumor cells through ADCC, whereby antibody-bound tumor cells are ligated by Fc receptors on NK cells and macrophages. ADCC is mediated by innate immune cells and does not require antigen-specific Tcell or B-cell responses. However, a role for adaptive immunity in the efficacy of mAbs has been proposed for aTRP1 as well as aher2neu and aCD20. This is because antibodies can modulate antigen presentation through ligation of Fc receptors on dendritic cells and other antigen-presenting cells (APC), which can then interact with and activate T cells, potentially converting passive immunization into active immunization (32) .
To test whether the adaptive immune system is required for efficacy of therapy with aTRP1 and cyclophosphamide, we treated Rag1 À/À mice lacking all adaptive lymphocyte populations, including B and T cells, with the combined therapy (33) . Therapeutic efficacy was completely preserved in Rag1 À/À mice ( Fig. 2A) , establishing that cell populations in the innate immune compartment are competent to mediate effective chemo-immunotherapy. Thus, therapeutic efficacy of chemotherapy combined with mAb is mediated by the innate immune compartment with requirement for Fc receptors.
Therapy with aTRP1 þ cyclophosphamide does not induce long-term protection against tumor reinoculation On the basis of results from the above experiments, we concluded that efficacy of our combination regimen is mediated by the innate immune system, most likely via ADCC. However, considerable evidence in the literature showed that mAbs can improve antigen presentation (34, 35) . We reasoned that adaptive immunity may be induced during treatment even if it is not essential for initial tumor clearance. Thus, we sought to test whether our combination regimen produces a vaccine-like effect. The value of successful immunotherapy is achieving long-term protection. To test whether chemo-immunotherapy induces long-term protection, we reinoculated surviving mice who did not exhibit tumor progression after treatment with cyclophosphamide and aTRP1 60 days after the previous challenge (Fig. 2B) . Survival was significantly improved in the treated mice compared with na€ ve controls, yet not improved relative to Control animals had received irradiated B16 60 days preceding tumor challenge and had not grown any visible tumors. Mice treated with combination immunotherapy did not have a significantly improved survival compared with mice previously exposed to irradiated B16 (P > 0.05), although they both had improved survival compared with completely na€ ve animals (P ¼ 0.0169 and P ¼ 0.0057, respectively).
untreated mice inoculated 60 days earlier with irradiated B16 cells. Thus, although some long-term protection was induced, it is attributable to exposure to the B16 cells and was not specific to immunotherapy with aTRP1 combined with cyclophosphamide. Furthermore, depletion of CD8 þ T cells, hypothesized to be activated through antibody-mediated cross-priming, did not affect the long-term protection that was achieved (Fig. 2B) . Thus, although prior exposure to B16 tumor cells confers a slight degree of protection, the addition of the antibody and cyclophosphamide does not further enhance long-term adaptive antitumor immunity. These results confirm an innate immune mechanism of action for this combination treatment.
mediate antitumor efficacy during treatment with chemo-immunotherapy As T and B cells are not required for efficacy of our treatment, and a protective T-cell response is not induced, we next tested whether lymphocytic populations, as opposed to myeloid cells, are critical for the efficacy of our combination regimen. We inoculated mice lacking the common gamma chain of the IL2 receptor (IL2gc
), which have a global defect in lymphocyte development (22) . Therapeutic efficacy was abrogated in IL2gc and Supplementary Fig. S2 ). Therefore, ILCs expressing CD90, but not NK cells, are required for antitumor response induced by this combined regimen.
NK1.1 À CD90 þ cells express RORgt and lack Fcg receptors
Innate lymphoid cells are dependent on the transcription factor Id2 and can be broadly classified into subgroups depending on their function and marker expression. LTi cells are characterized by their dependence on retinoic acid receptor-related orphan receptor gamma t (RORgt; ref. 24) . To better identify our cell population of interest, we analyzed the phenotype of NK1.1 À
CD90
þ cells. They were positive for the expression of RORgt and negative for NKp46 (Fig. 4C ). This is consistent with an ILC3/LTi phenotype (38) . To determine whether the NK1.1 À CD90 þ cells might mediate ADCC, we analyzed the population for expression of Fcg receptors. Our results show that these cells lack the expression of both FcgRI and FcgRII/III (Fig. 4C) . Anti-TRP1 mAb treatment efficacy is known to be dependent on FcgRI and FcgRIV in melanoma (19, 39, 40) , and our data highlight that activating Fc receptors are required for therapeutic efficacy of aTRP1 and cyclophosphamide. Thus, NK1.1 À CD90 þ cells are not likely the direct effectors of our combination therapy and must instead function as mediators in conjunction with other cells that express activating FcRs.
F4/80
þ macrophage cell infiltration is induced by cyclophosphamide and aTRP1 combination therapy and abrogated in CD90-depleted mice ILCs are known to regulate myeloid-cell populations and have been implicated in mediating antitumor efficacy via recruitment of other leukocytes into the tumor (37, 41) . Multiple prior studies have proposed a role for macrophages in the antitumor mechanism of anti-TRP1 (19, 40, 42) . To test the hypothesis that ILCs facilitate entry of macrophages, we examined the quantity and composition of myeloid cells infiltrating the tumor. These populations do not express CD90, and we confirmed this within the tumor setting (Supplementary Fig. S4 ). Depletion of CD90 þ lymphocytes resulted in a net reduction of macrophages and granulocyte receptor-1 antigen (Gr1) low myeloid cells, but not of Gr1 intermediate or Gr1 high myeloid cells (Fig. 5A-C) . These data show that CD90 þ cells alter the tumor microenvironment by modulating the numbers of macrophages and myeloid-derived suppressor cells entering into the tumor bed.
Discussion
Chemo-immunotherapy regimens using antitumor mAbs are widely used in clinical practice, inducing high response rates in patients with advanced solid tumors. However, the mechanisms of antitumor activity of chemo-immunotherapy in the clinic are not clearly delineated. In our study, we use an antibody targeting TRP1, a syngeneic antigen expressed on murine melanoma and melanocyte tissues, in combination with cyclophosphamide to treat established melanoma. TRP1 has been shown to be both an intracellular and a surface antigen on B16 tumor cells in vivo, making it a good target for antibody binding. This melanoma model is suitable to mimic the clinical setting in immunotherapy for solid tumors because the B16 cell line is not genetically manipulated and TRP1 antigen is endogenous to the mouse. Thus, there is low potential for artifact due to cross-species differences in protein sequence that can lead to adaptive immunity as may be observed in other models. Effect of CD90 depletion on infiltration of myeloid cells. A, mice (n ¼ 10-11) were treated with cyclophosphamide (CY) plus aTRP1 or with isotype control and administered either aCD90 i.p. or given isotype control. Each data point represents one animal. B, Gr-1 low CD11b þ immune suppressor cells had differences in CD90-depleted mice compared with CD90 þ mice (P ¼ 0.0076), while (C) Gr-1 high CD11b þ immune suppressor cells showed no significant difference in the two groups (P > 0.05). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.0001; ns, not statistically significant. We find that the antitumor activity of the combined aTRP1 mAb and cyclophosphamide regimen depends on Fc receptors, which are known to recognize mAbs bound to tumor antigen leading to ADCC and/or CDC (19) . This is consistent with several prior studies published by the Ravetch and Houghton laboratories using anti-TRP1 as a single agent (19, 25, 43, 44) . To distinguish between innate and adaptive immunity, we tested therapeutic efficacy in Rag1 À/À mice, which lack all adaptive immune responses. Strikingly, therapy was equally efficacious in both Rag1 À/À and control mice, highlighting the importance of innate immunity in the antitumor activity of this chemo-immunotherapeutic regimen. We show that efficacy is abrogated in IL2gc À/À mice lacking ILCs, and that depletion of CD90 þ cells, but not NK1.1 þ cells, impairs the efficacy of the combined aTRP1 mAb and cyclophosphamide regimen. Phenotyping the ILCs within the tumor revealed an absence of expression of Fc receptors. Thus, these cells most likely not direct effector cells in tumor suppression. However, depletion of CD90 þ cells also impaired macrophage penetration into the tumor, consistent with a role for macrophages in tumor clearance. Our data add to prior literature by confirming a predominately innate mechanism of action of the anti-TRP1 antibody and a previously proposed role for macrophages, while identifying a potential new role for ILCs in promoting tumor regression. Tumor eradication by anti-TRP1 combined with chemotherapy is mediated by the innate immune system. Our data complement work published by Park and colleagues (45) regarding the potential of chemotherapy to ablate the adaptive immune response induced by mAb therapy against her2neu. Thus, although there is significant evidence that chemotherapy at lower doses may be immune-stimulatory, higher doses required to induce significant tumor killing may adversely affect adaptive immune responses (26) . In this regard, our work differs in its conclusions from recent studies proposing a vaccine effect induced by mAbs (11, 45) . The fact that we do not observe significant long-term protection upon tumor rechallenge may be due to both the presence of the high-dose chemotherapy and the nature of our model where neither the antigen nor the tumor has been genetically manipulated to favor an adaptive immune response.
In this work, we do not wish to imply that T-cell responses cannot be induced by antibody. T-cell responses have been observed in breast cancer patients treated with anti-her2neu (46) , and intriguingly some activation of adoptively transferred anti-melanoma PMEL T cells did occur in the context of therapy as shown in Supplementary Fig. S5 . However, clinical experience with vaccine studies has demonstrated that heightened stimulation of peripheral T cells often does not translate into impactful antitumor immunity because of the immunosuppressive nature of the tumor microenvironment (47) (48) (49) . Thus, although minimal protective immunity was observed in longterm responders to initial treatment with aTRP1 þ cyclophosphamide, this immunity was not enhanced by inoculation with irradiated B16. This result suggests that the mild immunogenicity came from the B16 tumor cells and not from the combined therapy and that, in the context of high-dose cytotoxic chemotherapy, further immune stimulation would be required to produce clinically relevant long-term immunity. These results highlight the fact that long-term remission with strong protective immunity is rarely induced in solid tumors through combined mAb and chemotherapy.
Within the context of the innate immune system, our data highlight a potential role for NK1. 3 ILCs in the efficacy of chemo-immunotherapy in mice, the role of the human ILC3 counterpart may differ. Human ILC3s have been implicated in the development of colorectal carcinoma, wound repair, and the pathology in psoriasis (55) . Their role in melanoma is unknown. Furthermore, our findings suggest a different mechanism of function from that seen in ipilimumab and anti-PD-1 immunotherapy in which adaptive immunity plays a larger role (56) .
Our data identify CD90 þ NK1. 
